Feb8
9 February 2010 – US biotechnology company Cara Therapeutics Inc reported yesterday encouraging data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845.The 46-patient, Phase II, multi-centre, double-blind, placebo-controlled study was conducted at eight hospitals in the US and evaluated the efficacy and safety of CR845 in women following laparoscopic-assisted [...]
Feb7
SHELTON, Conn., Feb. 8 /PRNewswire/ Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States and evaluated the efficacy and safety of CR845 in women [...]
Dec17
2009 DEC 18 – (NewsRx.com) According to recent research from Tlaxcala, Mexico, "A spinal pattern generator controls the expression of ejaculation (see also Naloxone Therapy). When this ejaculation generator is activated it can be phasically controlled, at a spinal level, by intrinsic mechanisms that eventually lead to the establishment of both short- and long-lasting [...]
Dec15
According to recent research from Tlaxcala, Mexico, "A spinal pattern generator controls the expression of ejaculation. When this ejaculation generator is activated it can be phasically controlled, at a spinal level, by intrinsic mechanisms that eventually lead to the establishment of both short- and long-lasting inhibitory processes.""To evaluate the hypothesis that endogenous opioids participate in [...]
Oct6
Researchers in Sydney, Australia conducted a study "To examine the levels and predictors of injection of buprenorphine-naloxone (BNX) – a combination of a partial opioid agonist and an opioid antagonist for treating opioid dependence – which was specifically developed to limit injecting. Comparison was made with injecting of two other opioid substitution treatment medications, methadone [...]
Oct4
2009 OCT 5 – (NewsRx.com) Researchers in Sydney, Australia conducted a study "To examine the levels and predictors of injection of buprenorphine-naloxone (BNX) – a combination of a partial opioid agonist and an opioid antagonist for treating opioid dependence – which was specifically developed to limit injecting (see also Methadone). Comparison was made with [...]
Sep21
Sep 22, 2009 (Datamonitor via COMTEX) China Aoxing Pharmaceutical Company has reported that its clinical trial application for Tilidine/Naloxone capsules, an opioid drug with abuse resistance property, was officially approved by the China State Food and Drug Administration.Clinical trial application (CTA) approval is a key State Food and Drug Administration (SFDA) requirement prior to pursuing [...]
Sep16
NEW YORK, NY (MARKET WIRE) 09/17/09 China Aoxing Pharmaceutical Company, Inc.(OTCBB: CAXG) ("China Aoxing"), a China-based pharmaceutical companyspecializing in research, development, manufacturing and distribution ofnarcotic and pain-management products, today announced that its ClinicalTrial Application ("CTA") for Tilidine/Naloxone Capsules, an opioid drugwith abuse resistance property, was officially approved by the China StateFood and [...]
